Liver Metastasis Recruiting Phase 2 Trials for Nivolumab (DB09035)

IndicationStatusPhase
DBCOND0029622 (Liver Metastasis)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03785210Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic CancersTreatment